Physician profile
Mary E Walterhoefer
NPI 1831586718
$3,355.28
in general payments reported to CMS, 2019-2025
29 companies · $691 in 2025
The $691 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $186 · 2021: $358 · 2022: $347 · 2023: $888 · 2024: $698 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.96 |
| Education | $195.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $711.80 | 2020-2025 | Tremfya |
| Abbvie INC. | $411.79 | 2020-2024 | |
| Lilly USA, LLC | $206.75 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Revance Therapeutics, INC. | $194.02 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $168.26 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Novartis Pharmaceuticals Corporation | $151.37 | 2023-2025 | |
| Ucb, INC. | $139.44 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $129.55 | 2022-2025 | Dupixent |
| Genzyme Corporation | $114.20 | 2023-2025 | |
| Biofrontera INC. | $114.17 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $113.15 | 2022-2024 | Sotyktu |
| Amgen INC. | $107.71 | 2021-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $104.17 | 2023 | Ycanth |
| Strata Skin Sciences, INC. | $94.60 | 2022-2023 | Xtrac |
| Almirall LLC | $80.31 | 2021-2024 | Seysara |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $77.02 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $74.07 | 2019-2021 | |
| Merz North America, INC. | $69.01 | 2019-2022 | |
| Kyowa Kirin, INC. | $46.06 | 2023 | Poteligeo |
| Incyte Corporation | $44.63 | 2021-2023 | Opzelura |
| Epi Health, LLC | $41.59 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.67 | 2025 | Cabtreo |
| Vyne Pharmaceuticals INC. | $29.33 | 2020-2021 | |
| Botanix Sb INC | $21.88 | 2025 | Sofdra |
| Dermira, INC. | $19.79 | 2019 | |
| Encore Dermatology INC. | $19.77 | 2019 | |
| Lnhc, INC | $16.89 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $12.41 | 2019 | |
| Allergan, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Walterhoefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.